

## AMENDED FORM 9

### **NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES** **(or securities convertible or exchangeable into listed securities<sup>1</sup>)**

Please complete the following:

Name of Listed Issuer: ChroMedX Corp. (the "Issuer").

Trading Symbol: CHX

Date: June 19, 2017

Is this an updating or amending Notice: ☒ Yes ☐ No

If yes provide date(s) of prior Notices: June 14, 2017 and June 16, 2017

Issued and Outstanding Securities of Issuer Prior to Issuance: 68,384,764

Date of News Release Announcing Private Placement: \_\_\_\_\_

Closing Market Price on Day Preceding the Issuance of the News Release: The Issuer  
has a price reservation of \$0.20

**1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form)**

Full Name & Residential Address of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
Eric Salsberg North York, ON	250,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	3,750,000 Common Shares 950,000 Warrants	June 19, 2017	Non-Related Person
Barbara Scheurle Burlington, ON	50,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	65,000 Common Shares 100,000 Warrants	June 19, 2017	Non-Related Person
Roger Noke North York, ON	50,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	50,000 Common Shares 100,000 Warrants	June 19, 2017	Non-Related Person
William A. Gannon Medicine Professional Corporation Sarnia, ON	100,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	162,500 Common Shares 200,000 Warrant	June 19, 2017	Non-Related Person
Alexander Feness Etobicoke, ON	30,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	40,000 Common Shares 40,000 Warrants	June 19, 2017	Non-Related Person
Shaun Ruddy Toronto, ON	50,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	350,000 Common Shares 200,000 Warrants	June 19, 2017	Non-Related Person
L. Trigazis Medicine Professional Corporation Bolton, ON	50,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	50,000 Warrants	June 19, 2017	Non-Related Person

#### **FORM 9 – NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES**

Full Name & Residential Address of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
Barbara Pieters Calgary, AB	100,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	Nil	June 19, 2017	Non-Related Person
William Wine Port Hope, ON	100,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	Nil	June 19, 2017	Non-Related Person
Christine Cappuccitti Richmond Hill, ON	20,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	40,000 Common Shares 40,000 Warrants	June 19, 2017	Non-Related Person
Angelo Comi Etobicoke, ON	100,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	342,500 Common Shares 300,000 Warrants	June 19, 2017	Non-Related Person
Christine Comi Toronto, ON	50,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	965,000 Common Shares 700,000 Warrants	June 19, 2017	Non-Related Person
John Comi Toronto, ON	50,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	965,000 Common Shares 700,000 Warrants	June 19, 2017	Non-Related Person
Current Market Communications and Associates Inc. Toronto, ON	100,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	370,000 Common Shares 100,000 Warrants	June 19, 2017	Non-Related Person
John Purdy Toronto, ON	200,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	Nil	June 19, 2017	Non-Related Person
Ed Blasiak Toronto, ON	100,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.3 of NI 45-106	300,000 Common Shares	June 19, 2017	Non-Related Person
Greg Falck Comox, BC	12,500 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	Nil	June 19, 2017	Non-Related Person
Zurich Global Corp. Brooklyn, NY	100,000 Units	\$0.20	Warrant exercisable at \$0.30	N/A	Nil	June 19, 2017	Non-Related Person
Aron Fessaha Toronto, ON	200,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	100,000 Common Shares	June 19, 2017	Non-Related Person
Fairmont Advisors LLC New York, NY	250,000 Units	\$0.20	Warrant exercisable at \$0.30	N/A	Nil	June 19, 2017	Non-Related Person
Sarah Graham Toronto, ON	50,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	Nil	June 19, 2017	Non-Related Person
Babita Kaushal Mississauga, ON	100,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	Nil	June 19, 2017	Non-Related Person
George Langdon Yucatan, Mexico	100,000 Units	\$0.20	Warrant exercisable at \$0.30	N/A	1,650,000 Common Shares	June 19, 2017	Related Person
Mario Berket Toronto, ON	500,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	1,000,000 Common Shares	June 19, 2017	Non-Related Person
Mario Berket Toronto, ON	225,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	1,000,000 Common Shares	June 19, 2017	Non-Related Person
Alex Falconer Burlington, ON	50,000 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	280,000 Common Shares	June 19, 2017	Non-Related Person
Wayne Maddever Burlington, ON	112,500 Units	\$0.20	Warrant exercisable at \$0.30	Section 2.5 of NI 45-106	600,000 Common Shares	June 19, 2017	Non-Related Person

**FORM 9 – NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES**

January 2015

Page 2

- (1) Indicate date each placee advanced or is expected to advance payment for securities. Provide details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals.
- (2) Indicate if Related Person.

<sup>1</sup>An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: \$620,000 .
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. Developing prototypes, marketing and general working capital purposes .
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: Not applicable .
4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities. Not applicable .
5. Description of securities to be issued:
- (a) Class Units ("Units") of the Issuer. Each Unit will be comprised of one common share (a "**Common Share**") and one Common Share purchase warrant (a "**Warrant**"). Each Warrant entitling the holder thereof to acquire one Common Share at a price of \$0.30 for a period of eighteen (18) months from the closing date. .
- (b) Number 3,100,000 Units .
- (c) Price per security \$0.20 per Unit .
- (d) Voting rights 1 vote per common share .
6. Provide the following information if Warrants, (options) or other convertible securities are to be issued:
- (a) Number 3,100,000 Warrants .
- (b) Number of securities eligible to be purchased on exercise of Warrants (or options) 3,100,000 Common Shares .
- (c) Exercise price \$0.30 .
- (d) Expiry date 18 months from date of issuance .

---

**FORM 9 – NOTICE OF PROPOSED ISSUANCE OF  
LISTED SECURITIES**

7. Provide the following information if debt securities are to be issued:
- (a) Aggregate principal amount \_\_\_\_\_ .
  - (b) Maturity date \_\_\_\_\_ .
  - (c) Interest rate \_\_\_\_\_ .
  - (d) Conversion terms \_\_\_\_\_ .
  - (e) Default provisions \_\_\_\_\_ .
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):  
  
Cash commission equal to 8% of the gross proceeds raised and broker warrants ("Broker Warrants") equal to 8% of the Units sold. Each Broker Warrant entitling the holder thereof to purchase one Common Share at a price of \$0.20 for eighteen (18) months from the date of issuance. .
  - (b) Cash \$16,000 .
  - (c) Securities 80,000 Broker Warrants .
  - (d) Other Not applicable .
  - (e) Expiry date of any options, warrants etc. 18 months .
  - (f) Exercise price of any options, warrants etc. \$0.20 .
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship \_\_\_\_\_  
Not applicable .
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).  
Not applicable .

11. State whether the private placement will result in a change of control.  
No .
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. Not applicable .
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102.

## **2. Acquisition**

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: \_\_\_\_\_ .
2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: \_\_\_\_\_ .
3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:
- (a) Total aggregate consideration in Canadian dollars: \_\_\_\_\_ .
  - (b) Cash: \_\_\_\_\_ .
  - (c) Securities (including options, warrants etc.) and dollar value: \_\_\_\_\_ .
  - (d) Other: \_\_\_\_\_ .
  - (e) Expiry date of options, warrants, etc. if any: \_\_\_\_\_ .
  - (f) Exercise price of options, warrants, etc. if any: \_\_\_\_\_ .
  - (g) Work commitments: \_\_\_\_\_ .

4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: \_\_\_\_\_  
\_\_\_\_\_.
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer <sup>(1)</sup>

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: \_\_\_\_\_  
\_\_\_\_\_.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
  - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): \_\_\_\_\_  
\_\_\_\_\_.
  - (b) Cash \_\_\_\_\_.
  - (c) Securities \_\_\_\_\_.
  - (d) Other \_\_\_\_\_.
  - (e) Expiry date of any options, warrants etc. \_\_\_\_\_.
  - (f) Exercise price of any options, warrants etc. \_\_\_\_\_.
9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_.

**FORM 9 – NOTICE OF PROPOSED ISSUANCE OF  
LISTED SECURITIES**

10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. \_\_\_\_\_.

### **Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated June 19, 2017 \_\_\_\_\_.

Ash Kaushal  
Name of Director or Senior  
Officer

"Ash Kaushal" (Signed)  
Signature

Chief Executive Officer  
Official Capacity